肝细胞癌免疫治疗耐药机制研究现状

摘要/Abstract

摘要： 肝癌是全球第六大原发性癌症,也是世界癌症相关死亡的第四大原因。其中,肝细胞癌(HCC)约占肝癌的90%。由于其发病隐匿,80%以上的患者确诊时已为中晚期,致使HCC成为重大的医疗负担。尽管免疫治疗在晚期HCC治疗中取得了重大进展,但仅有20%~30%的患者对免疫治疗有效。这表明HCC肿瘤微环境(TME)通过复杂的机制导致了免疫检查点抑制剂(ICI)的耐药。阐明其耐药机制对于重塑免疫微环境以及提高治疗疗效具有重要意义。本文概述了HCC免疫抑制微环境及免疫治疗原发性耐药、获得性耐药机制,为未来HCC耐药治疗研究提供参考。

关键词: 肝细胞癌, 免疫治疗, 肿瘤微环境, 原发性耐药, 获得性耐药

代欣, 曹博然, 李丹, 袁雅琴, 李斌. 肝细胞癌免疫治疗耐药机制研究现状[J]. 肝脏, 2022, 27(10): 1059-1061.

参考文献

[1] Donne R, Lujambio A. The Liver Cancer Immune Microenvironment: Therapeutic Implications for Hepatocellular Carcinoma. Hepatology,2022.
[2] Kubes P, Jenne C. Immune Responses in the Liver. Annu Rev Immunol,2018,36:247-277.
[3] Shi F, Shi M, Zeng Z, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer,2011,128:887-896.
[4] Shang S, Zhao Y, Qian K, et al. The role of neoantigens in tumor immunotherapy. Biomed Pharmacother,2022,151:113118.
[5] Fujimoto A, Furuta M, Totoki Y, et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet, 2016,48:500-509.
[6] Lurje I, Hammerich L, Tacke F. Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer. Int J Mol Sci, 2020,21(19):7378.
[7] Liu Z, Ning F, Cai Y, et al. The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells. Cancer Commun (Lond), 2021,41:62-78.
[8] Harkus U, Wankell M, Palamuthusingam P, et al. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data. Semin Cancer Biol,2022,86(Pt 3):799-815..
[9] Tu JF, Ding YH, Ying XH, et al. Regulatory T cells, especially ICOS(+) FOXP3(+) regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival. Sci Rep,2016,6:35056.
[10] Langhans B, Nischalke HD, Kramer B, et al. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma. Cancer Immunol Immunother, 2019,68:2055-2066.
[11] Ngiow SF, Young A, Jacquelot N, et al. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res,2015,75:3800-3811.
[12] Zhao C, Pang X, Yang Z, et al. Nanomaterials targeting tumor associated macrophages for cancer immunotherapy. J Control Release,2022,341:272-284.
[13] Yeung OW, Lo CM, Ling CC, et al. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. J Hepatol,2015,62:607-616.
[14] Zabransky DJ, Danilova L, Leatherman JM, et al. Profiling of murine syngeneic HCC tumor models as a framework to understand anti-PD-1 sensitive tumor microenvironments. Hepatology,2022.
[15] Wei CY, Zhu MX, Zhang PF, et al. PKCalpha/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. J Hepatol, 2022,77:163-176.
[16] Li Z, Wu T, Zheng B, et al. Individualized precision treatment: Targeting TAM in HCC. Cancer Lett, 2019,458:86-91.
[17] Tesi RJ. MDSC; the Most Important Cell You Have Never Heard Of. Trends Pharmacol Sci, 2019,40:4-7.
[18] Tomiyama T, Itoh S, Iseda N, et al. Myeloid-derived suppressor cell infiltration is associated with a poor prognosis in patients with hepatocellular carcinoma. Oncol Lett,2022,23:93.
[19] Martens A, Wistuba-Hamprecht K, Geukes Foppen M, et al. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clin Cancer Res,2016,22:2908-2918.
[20] Ruiz de Galarreta M, Bresnahan E, Molina-Sanchez P, et al. beta-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discov,2019,9:1124-1141.
[21] Morita M, Nishida N, Sakai K, et al. Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody. Liver Cancer, 2021,10:380-393.
[22] Matsuda A, Ishiguro K, Yan IK, et al. Extracellular Vesicle-Based Therapeutic Targeting of beta-Catenin to Modulate Anticancer Immune Responses in Hepatocellular Cancer. Hepatol Commun,2019,3:525-541.
[23] Shin DS, Zaretsky JM, Escuin-Ordinas H, et al. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov,2017,7:188-201.
[24] Shrestha R, Bridle KR, Crawford DHG, et al. Immune checkpoint molecules are regulated by transforming growth factor (TGF)-beta1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma. Int J Med Sci,2021,18:2466-2479.
[25] Mariathasan S, Turley SJ, Nickles D, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature,2018,554:544-548.
[26] Riaz N, Havel JJ, Makarov V, et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell,2017,171:934-949 e16.
[27] Mantovani S, Oliviero B, Varchetta S, et al. Natural Killer Cell Responses in Hepatocellular Carcinoma: Implications for Novel Immunotherapeutic Approaches. Cancers (Basel),2020,12.
[28] Barsch M, Salie H, Schlaak AE, et al. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. J Hepatol,2022,77:397-409.